FDA Adverse Event Injury Summary report: N

MOSAIC AORTIC BIOPROSTHETIC HEART VALVE

MDR report key: 20697672 · Received November 15, 2024

Report

Report Number
2025587-2024-06578
Event Type
Injury
Date Received
November 15, 2024
Date of Event
June 6, 2024
Report Date
November 15, 2024
Manufacturer
MEDTRONIC HEART VALVES DIVISION
Product Code
DYE
PMA / PMN Number
P990064
Adverse Event
Yes
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
GM
Reporter Occupation
PHYSICIAN
Health Professional
Yes

Narratives

Additional Manufacturer Narrative · 0

MEDTRONIC SUBMITS THIS REPORT TO COMPLY WITH FDA REGULATIONS 21 CFR PARTS 4 AND 803. MEDTRONIC HAS MADE REASONABLE EFFORTS TO PROVIDE AS MUCH RELEVANT INFORMATION AS IS AVAILABLE TO THE COMPANY AS OF THE SUBMISSION DATE OF THIS REPORT. THIS REPORT DOES NOT CONSTITUTE AN ADMISSION OR A CONCLUSION BY FDA, MEDTRONIC, OR ITS EMPLOYEES THAT THE DEVICE, MEDTRONIC, OR ITS EMPLOYEE CAUSED OR CONTRIBUTED TO THE EVENT DESCRIBED IN THE REPORT. ANY REQUIRED FIELDS THAT ARE UNPOPULATED ARE BLANK BECAUSE THE INFORMATION IS CURRENTLY UNKNOWN OR UNAVAILABLE. MEDTRONIC WILL SUBMIT A SUPPLEMENTAL REPORT IF ADDITIONAL RELEVANT INFORMATION BECOMES KNOWN.

Additional Manufacturer Narrative · 0

CITATION: MICHAELA GRASER, ET AL. IMPACT OF PATIENT-PROSTHESIS MISMATCH ON LONG-TERM OUTCOMES AFTER AORTIC VALVE REPLACEMENT. THE ANNALS OF THORACIC SURGERY. JUNE 6, 2024; 118(5):1063-1070. DOI.ORG/10.1016/J.ATHORACSUR.2024.05.025 EARLIEST DATE OF PUBLICATION USED FOR DATE OF EVENT NO UNIQUE DEVICE IDENTIFIER (SERIAL/LOT) NUMBERS WERE PROVIDED; WITHOUT THIS INFORMATION IT COULD NOT BE DETERMINED WHETHER THESE OBSERVATIONS HAVE BEEN PREVIOUSLY REPORTED. WITHOUT RETURN OF THE PRODUCT NO DEFINITIVE CONCLUSION CAN BE MADE REGARDING THE CLINICAL OBSERVATIONS. MEDTRONIC SUBMITS THIS REPORT TO COMPLY WITH FDA REGULATIONS 21 CFR PARTS 4 AND 803. MEDTRONIC HAS MADE REASONABLE EFFORTS TO PROVIDE AS MUCH RELEVANT INFORMATION AS IS AVAILABLE TO THE COMPANY AS OF THE SUBMISSION DATE OF THIS REPORT. THIS REPORT DOES NOT CONSTITUTE AN ADMISSION OR A CONCLUSION BY FDA, MEDTRONIC, OR ITS EMPLOYEES THAT THE DEVICE, MEDTRONIC, OR ITS EMPLOYEE CAUSED OR CONTRIBUTED TO THE EVENT DESCRIBED IN THE REPORT. ANY REQUIRED FIELDS THAT ARE UNPOPULATED ARE BLANK BECAUSE THE INFORMATION IS CURRENTLY UNKNOWN OR UNAVAILABLE. MEDTRONIC WILL SUBMIT A SUPPLEMENTAL REPORT IF ADDITIONAL RELEVANT INFORMATION BECOMES KNOWN.

Description of Event or Problem · 0

LITERATURE WAS REVIEWED REGARDING THE IMPACT OF PATIENT-PROSTHESIS MISMATCH ON LONG-TERM OUTCOMES AFTER AORTIC VALVE REPLACEMENT. THE STUDY POPULATION INCLUDED 645 PATIENTS WITH A MEAN AGE OF 73 YEARS WHO WERE PREDOMINANTLY MALES. MULTIPLE MANUFACTURER¿S DEVICES WERE IMPLANTED IN THE STUDY POPULATION; 45 PATIENTS WERE IMPLANTED WITH A MEDTRONIC MOSAIC BIOPROSTHETIC VALVE. DEATHS OCCURRED IN THE STUDY POPULATION; HOWEVER, THERE WAS NO STATEMENT ESTABLISHING A CAUSAL OR CONTRIBUTORY RELATIONSHIP BETWEEN MEDTRONIC PRODUCT AND THE DEATHS. AMONG ALL PATIENTS, ADVERSE EVENTS INCLUDED: PATIENT-PROSTHESIS MISMATCH, STENOSIS, REGURGITATION AND ENDOCARDITIS. IT WAS REPORTED THAT SOME PATIENTS HAD TO UNDERGO REINTERVENTIONS ON THE AORTIC VALVE, EITHER AS REDO SURGICAL VALVE REPLACEMENT OR AS CATHETER-BASED INTERVENTION. NO FURTHER INFORMATION WAS PROVIDED PERTAINING TO MEDTRONIC PRODUCTS.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
56559 MOSAIC AORTIC BIOPROSTHETIC HEART VALVE REPLACEMENT HEART-VALVE DYE MEDTRONIC HEART VALVES DIVISION 30519

Patients

Seq Age Sex Outcome Treatment
1 73 YR Male Life Threatening| R| H